Shir Dror, Shiner Tamara, Bregman Noa
Cognitive Neurology Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel.
Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Tel Aviv-Yafo, Israel.
J Alzheimers Dis. 2024 Dec;102(3):627-632. doi: 10.1177/13872877241289788. Epub 2024 Oct 29.
Advances in amyloid targeting therapies (ATT) for Alzheimer's disease have introduced new options, necessitating an understanding of physicians' perspectives as these therapies move from trials to practice. A survey of Israeli specialists found that 84% were familiar with new ATT, but 60% raised doubts about their ability to significantly impact disease progression. Neurologists were more likely to recommend these treatments, but concerns included treatment costs and limited real-world experience. The decision to refer patients was influenced by patient age, financial status, and diagnostic test availability. Strategies to enhance physician education and improve patient access to ATT are suggested.
阿尔茨海默病淀粉样蛋白靶向疗法（ATT）的进展带来了新的选择，随着这些疗法从试验阶段进入实际应用阶段，有必要了解医生的观点。一项对以色列专家的调查发现，84%的人熟悉新的ATT，但60%的人对其显著影响疾病进展的能力表示怀疑。神经科医生更有可能推荐这些治疗方法，但担忧包括治疗成本和有限的真实世界经验。转诊患者的决定受到患者年龄、财务状况和诊断测试可用性的影响。文中提出了加强医生教育和改善患者获得ATT的策略。
